- Home
- BIIB vs JBL Comparison
BIIB vs JBL Comparison
Compare BIIB & JBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- JBL
- Stock Information
- Founded
- BIIB 1978
- JBL 1966
- Country
- BIIB United States
- JBL United States
- Employees
- BIIB 7605
- JBL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- JBL Electrical Products
- Sector
- BIIB Health Care
- JBL Technology
- Exchange
- BIIB Nasdaq
- JBL Nasdaq
- Market Cap
- BIIB 20.6B
- JBL 18.6B
- IPO Year
- BIIB 1991
- JBL 1993
- Fundamental
- Price
- BIIB $140.60
- JBL $162.63
- Analyst Decision
- BIIB Buy
- JBL Buy
- Analyst Count
- BIIB 27
- JBL 7
- Target Price
- BIIB $220.50
- JBL $155.67
- AVG Volume (30 Days)
- BIIB 1.5M
- JBL 1.1M
- Earning Date
- BIIB 02-12-2025
- JBL 03-14-2025
- Dividend Yield
- BIIB N/A
- JBL 0.20%
- EPS Growth
- BIIB 40.28
- JBL 83.88
- EPS
- BIIB 11.18
- JBL 10.81
- Revenue
- BIIB $9,675,900,000.00
- JBL $27,490,000,000.00
- Revenue This Year
- BIIB N/A
- JBL N/A
- Revenue Next Year
- BIIB $1.57
- JBL $5.31
- P/E Ratio
- BIIB $12.65
- JBL $14.98
- Revenue Growth
- BIIB N/A
- JBL N/A
- 52 Week Low
- BIIB $128.51
- JBL $95.85
- 52 Week High
- BIIB $238.00
- JBL $174.80
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- JBL 49.60
- Support Level
- BIIB $135.02
- JBL $168.13
- Resistance Level
- BIIB $141.69
- JBL $171.45
- Average True Range (ATR)
- BIIB 4.00
- JBL 3.35
- MACD
- BIIB 0.04
- JBL -0.89
- Stochastic Oscillator
- BIIB 59.44
- JBL 43.86
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About JBL Jabil Inc.
Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.